Tacrolimus vs Crisaborole Atopic Dermatitis 8-Week Trial
Summary
ClinicalTrials.gov registered a new randomized controlled trial comparing tacrolimus ointment versus crisaborole ointment for treating atopic dermatitis in participants 12 years and older over an 8-week period. The single-center study being conducted in the United States is estimated to enroll 80 participants and is currently recruiting.
What changed
A new clinical trial (NCT07519174) was registered on ClinicalTrials.gov comparing tacrolimus ointment (0.1% and 0.03%) to crisaborole ointment (2%) for treating mild to severe atopic dermatitis over 8 weeks. The randomized controlled trial will enroll approximately 80 participants aged 12 and older at a single US site.
Healthcare providers and patients considering atopic dermatitis treatment options should note this comparative effectiveness study may inform future prescribing decisions. Pharmaceutical manufacturers of both drugs may use trial results for regulatory submissions or marketing purposes.
What to do next
- Monitor for enrollment updates
- Review eligibility criteria if considering participation
Archived snapshot
Apr 10, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Show glossary
Related changes
Get daily alerts for ClinicalTrials.gov
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from NLM.
The plain-English summary, classification, and "what to do next" steps are AI-generated from the original text. Cite the source document, not the AI analysis.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when ClinicalTrials.gov publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.